Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on August 16, 2004

Circulation. 2004
Published online before print August 16, 2004, doi: 10.1161/01.CIR.0000139985.81163.CE
A more recent version of this article appeared on August 24, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
110/8/915    most recent
01.CIR.0000139985.81163.CEv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhao, S. P.
Right arrow Articles by Li, Y. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhao, S. P.
Right arrow Articles by Li, Y. L.
Related Collections
Right arrow Nutrition
Right arrow Cardiovascular Pharmacology
Right arrow Doppler ultrasound, Transcranial Doppler etc.
Right arrow Chronic ischemic heart disease
Right arrow Lipid and lipoprotein metabolism
Right arrow Endothelium/vascular type/nitric oxide

Submitted on January 22, 2003
Revised on January 13, 2004
Accepted on April 20, 2004

Xuezhikang, an Extract of Cholestin, Protects Endothelial Function Through Antiinflammatory and Lipid-Lowering Mechanisms in Patients With Coronary Heart Disease

Shui Ping Zhao MD, PhD*, Ling Liu MD, PhD, Yan Chun Cheng MD, PhD, Mehdi H. Shishehbor DO, Ming Hui Liu MD, Dao Quan Peng MD, PhD, and Yu Ling Li MD

From the Departments of Cardiology (S.P.Z., L.L., Y.C.C., D.Q.P.), Ultrasound (M.H.L.), and Nutrition (Y.L.L.), Second Xiangya Hospital, Central South University, Hunan, China; and Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio (M.H.S.).

Background--Endothelial dysfunction is associated with inflammation and postprandial hypertriglyceridemia. Xuezhikang, an extract of Cholestin, a dietary supplement, has lipid-modulating and antiinflammatory effects. We explored the effects of xuezhikang on endothelial function and high-sensitivity C-reactive protein (hs-CRP) in patients with coronary heart disease (CHD).

Methods and Results--We prospectively randomized 50 CHD patients to xuezhikang 1200 mg/d or placebo for 6 weeks. Fasting hs-CRP concentrations, flow-mediated vasodilation (FMD) at 0 and 4 hours, and lipid parameters at 0, 2, 4, and 6 hours were monitored after a high-fat meal (800 calories; 50 g fat) in all patients. All patients underwent a high-fat meal test at the beginning of the study and after 6 weeks of treatment. Postprandial FMD was significantly worse at 4 hours after a high-fat meal (P<0.05), and this was associated with the area under the triglyceride curve (TG-AUC) (r=0.345, P<0.01). After 6 weeks of xuezhikang, fasting hs-CRP levels and TG-AUC (P<0.001 for each) decreased. Furthermore, preprandial and postprandial FMD significantly improved (P<0.001). There were no significant changes in serum lipids and FMD in the placebo arm. In multivariable regression analysis, changes in TG-AUC and fasting hs-CRP levels were predictive of improvement in preprandial FMD (P<0.05).

Conclusions--Xuezhikang effectively improved preprandial and postprandial endothelial function through its potent antiinflammatory and lipid-lowering effects.


Key words: postprandial period • vasodilation • blood flow • coronary disease • xuezhikang




This article has been cited by other articles:


Home page
J Clin PharmacolHome page
J.-J. Li, Z.-L. Lu, W.-R. Kou, Z. Chen, Y.-F. Wu, X.-H. Yu, Y.-C. Zhao, and on behalf of the Chinese Coronary Secondary Preven
Beneficial Impact of Xuezhikang on Cardiovascular Events and Mortality in Elderly Hypertensive Patients With Previous Myocardial Infarction From the China Coronary Secondary Prevention Study (CCSPS)
J. Clin. Pharmacol., August 1, 2009; 49(8): 947 - 956.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
P. C. Kao, S.-C. Shiesh, and T.-J. Wu
Serum C-reactive protein as a marker for wellness assessment.
Ann. Clin. Lab. Sci., March 1, 2006; 36(2): 163 - 169.
[Abstract] [Full Text] [PDF]